Gujarat Themis Biosyn Ltd

Gujarat Themis Biosyn Acquires Sanofi’s Anti-TB Portfolio 🌍💊

- Acquired 13 branded generic products from Sanofi with €62M in 2025 sales

- Portfolio spans Europe, Middle East, and Africa across 55+ countries

- Purchase price is €158M, funded via debt and equity

- Deal includes marketing rights, brands, and inventory—no facilities or employees

- Expected to close by December 31, 2026

- Aims to improve margins through backward integration

- Supports GTBL’s forward integration strategy using fermentation-based APIs

- Focuses on TB elimination and antimicrobial resistance trends